35 results about "Malaria" patented technology

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions containing such antibodies, methods for producing the disclosed antibodies, and methods for using them to treat or prevent malaria, as well as methods for selecting antibodies as anti-malaria therapeutic antibodies.

This invention provides compounds for the treatment, prevention, or suppression of various pathological conditions (such as proliferative disorders like cancer, β-globin disorders, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism) by inhibiting G9a. [Solution] The following general formula (I) TIFF2026062914000401.tif2449 A compound represented by or a pharmacoposly acceptable salt thereof is provided.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

Compounds of formula (I) or their pharmaceutically acceptable salts, hydrates, solvates, esters or their optical isomers, racemates, diastereoisomers, enantiomers, tautomers, or a mixture thereof; said compounds exhibits anti-plasmidal activities, in particular for the treatment of malaria diseases.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The utility model relates to the technical field of medical detection, in particular to a malaria colloidal gold kit capable of improving rapid detection efficiency, which comprises a kit body and a blood taking needle, the side wall of the kit body is provided with two notches, and the inner side of the kit body is fixedly provided with detection test paper; a clamping structure is mounted on the kit body and comprises a rotating shaft I rotationally connected to the side wall of the kit body. The blood taking needle is clamped and fixed through the clamping structure, so that the kit body is provided with the disposable blood taking needle in a matched mode, the disposable blood taking needle does not need to be cleaned after being used, the detection speed is greatly increased, dropped blood and buffering agents can be stirred through the stirring structure, and the detection accuracy is improved. Therefore, the mixing of the blood and the buffering agent is promoted.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

This invention relates to antibodies for the treatment or prevention of malaria.

This disclosure relates to a compound represented by formula I:(I) and a method for treating malaria parasitic infection, the method comprising administering the compound represented by formula I or a pharmaceutically acceptable salt thereof to a person in need of such treatment. [Formula 1] TIFF2026520957000151.tif23115

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that exhibit potent antimalarial activity against multiple strains of Plasmodium spp. in the parasite's various stages, such as, for example, the erythrocytic and exoerythrocytic stages, and pharmaceutical compositions comprising same. In one aspect, the compounds are tetrahydroacridinones having the structure I described herein. In another aspect, the compounds described herein can be used to treat or prevent malaria in a subject.

This application relates to compositions comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in reducing or preventing the transmission of malaria and dengue fever, and corresponding methods. This application also relates to 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in inhibiting the development of protozoa into ookinetes, oocysts, or sporozoites, and to mosquito baits comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof and one or more sugar sources.

The application discloses a novel Kdo-MPLA adjuvant, relates to the technical field of synthetic biology, and discloses that the adjuvant is composed of monophosphoryl lipid A (MPLA) and Kdo sugar through an alpha-glycosidic bond, the MPLA is a structure of Salmonella lipid A modified by monophosphorylation at a 4' position, and the Kdo sugar is endowed with amphiphilicity, so that the Kdo sugar is self-assembled into a liposome nanoparticle in an aqueous solution; the attenuated strain of Salmonella is edited by double knockout of rfaC and eptA genes: the rfaC knockout blocks the synthesis of LPS core polysaccharide and retains the lipid A-Kdo connection; the eptA knockout obtains monophosphorylated lipid A; after fermentation of the engineering bacteria, high-purity Kdo-MPLA is obtained by using a phenol-chloroform-petroleum ether extraction method, the process is simplified, and the product is uniform; the adjuvant can activate a TLR4 signal pathway and induce a Th1 type immune response, and the levels of inflammatory factors IL-6 and IL-1beta are significantly lower than those of natural LPS, so that the adjuvant is suitable for a mixed preparation of HPV, malaria and other vaccine antigens; and the application overcomes the uncontrollability of hydrolysis and the high cost defect of chemical synthesis of a traditional MPLA chemical extraction process.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The embodiment of the invention relates to a sample analysis method of a sample analyzer. The sample analysis method comprises the following steps: sucking a to-be-detected blood sample; mixing at least one part of the blood sample to be detected, the hemolytic agent, the first fluorescent dye and the second fluorescent dye to prepare a detection sample at a time; in a single test, each particle in a measurement sample is passed through an optical detection zone irradiated by excitation light to acquire optical information of the measurement sample, the excitation light including light of a first wavelength capable of exciting a first fluorescent dye and light of a second wavelength capable of exciting a second fluorescent dye, the second wavelength being greater than the first wavelength, the optical information comprises a first fluorescent signal corresponding to the first fluorescent dye and a second fluorescent signal corresponding to the second fluorescent dye, which are obtained in a single test; and obtaining infected red blood cell information of the measurement sample based on the first fluorescence signal and the second fluorescence signal. Therefore, the infected red blood cell information can be quickly and accurately obtained to assist malaria diagnosis.

Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects.

The invention provides a lysis buffer for targeted removal of red blood cells, a red blood cell lysis method and application thereof, and belongs to the technical field of red blood cell lysis. The lysate consists of a plasmodium merozoite extract, soybean plant hemagglutinin and a liquid-based cell preservation solution, wherein the liquid-based cell preservation solution is an aqueous solution containing glycyrrhizic acid, disodium ethylene diamine tetraacetate, disodium hydrogen phosphate, sodium chloride, potassium chloride and monopotassium phosphate. According to the method disclosed by the invention, the plasmodium merozoite extract and the soybean plant hemagglutinin are combined to quickly degrade protein and lipid which are key components of an erythrocyte membrane and destroy the integrity of a membrane structure, so that erythrocyte rupture is finally caused, and no adverse effect is caused on visible components such as other cells while the erythrocyte is efficiently and quickly removed.

To provide methods and compositions for treating and preventing malaria.SOLUTION: The present disclosure provides immunogenic compositions for inducing an immune response against malaria. The present disclosure also provides novel methods of administering the immunogenic compositions. Disclosed herein are methods and compositions for treating malaria by administering an immunogenic composition. The compositions benefit from the use of saponin-based adjuvants which provide particularly enhanced immune responses. In embodiments, provided herein are immunogenic compositions comprising an antigen of a Plasmodium parasite.SELECTED DRAWING: None

The present invention provides: a compound having an antimalarial action or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same, in particular, a preventative agent and / or a therapeutic agent for malaria.　The present invention provides a compound represented by formula (I). (In the formula: Z represents -CR6aR6b-CR7aR7b- or the like; R6a, R6b, R7a, and R7b each independently represent a hydrogen atom or the like; R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom or the like; R3 represents a hydrogen atom or the like; R4 represents a hydrogen atom or the like; L1 represents -CR9aR9b- or the like; R9a and R9b each independently represent a hydrogen atom or the like; L2 represents a single bond or the like; and R5 represents a substituted or unsubstituted aromatic carbon ring group or the like.)

Disclosed herein are methods and apparatus for making a determination whether a blood sample is, or is not, infected with a malaria parasite. The determination is made using a trained machine-learning (ML) algorithm. In some aspects, a microfluidic chip is used for the concentration of red blood cells infected with these parasites from uninfected red blood cells, the staining of the blood sample which differentially stains infected and uninfected red blood cells, and holds the sample of interest for imaging. The microfluidic chip is inserted into an optical subsystem that magnifies the image created from transmitted light microscopy. The magnified image is captured with a camera, and a trained ML algorithm assesses if the sample does or does not contain the parasite. Generally, the ML algorithm is executed on a portable computing device such as a smartphone.

The present invention relates to antigens, antibodies and vaccines for treatment or prevention of malaria.

The invention provides an application of an indoleamine compound. Specifically, the invention provides an application of a compound shown as a formula I, an optical isomer, a cis-trans-isomer or a pharmaceutically acceptable salt thereof, and the compound shown as the formula I is an indole compound, has excellent and broad-spectrum insecticidal activity, and is beneficial to development of a novel high-efficiency, low-toxicity, safe and environment-friendly insecticide. The invention also relates to a composition of the compound and application of the composition in killing and / or preventing pests and inhibiting malaria spread by mosquitoes.

The invention is in the field of vaccines, particularly in the field of polypeptide vaccines that target malaria. Malaria is caused by a parasite that is transmitted by mosquitoes. Transmission- blocking vaccines can prevent transmission from human to mosquito and thus can prevent spread of the disease. The invention provides polypeptides that show remarkable efficiency when used in a transmission-blocking vaccine strategy.

This invention relates to a 6- O -L-arabinopyranosyl- β The preparation of β-D-glucopyranoside and its application in the preparation of antimalarial products belong to the field of traditional Chinese medicine and natural drug pharmaceuticals. Compound 6- of this invention... O -L-arabinopyranosyl- β This invention relates to an antimalarial drug with β-D-glucopyranoside as the active ingredient. It expands the application of aromatic disaccharide compounds 6- from *Hydrangea macrophylla*. O -L-arabinopyranosyl- β The medicinal value of D-glucopyranoside.

The application discloses an AKK and / or outer membrane vesicle thereof induced macrophage polarization method and application thereof in preparation of a medicine for promoting phagocytosis of infected red blood cells by macrophages, and belongs to the technical field of biological medicines. It is found by the application that macrophages are subjected to M1 polarization phenomenon after being induced by AKK bacteria or OMVs thereof. The macrophages subjected to M1 polarization produce proinflammatory factors, and phagocytose more red blood cells infected by Plasmodium. In the absence of existing anti-malaria medicines, compared with macrophages not subjected to M1 polarization, the macrophages subjected to M1 polarization only by AKK bacteria or AKK-OMVs can phagocytose more red blood cells infected by Plasmodium, effectively avoiding the resistance of Plasmodium to anti-malaria medicines caused by long-term use of the anti-malaria medicines, and providing a new scheme for clinical malaria treatment.